Quick Answer: The Anthropic IPO will list Class A common stock on Nasdaq under the ticker ANT. The roadshow has started, pricing is expected November 18, and trading is expected November 19. The estimated U.S. offering price is $70 to $78 per share, subject to regulatory clearance, investor demand, and market conditions.
The Anthropic IPO puts two very different numbers in front of retail investors at once. One says the company lost $23.3 billion last quarter. Another says the European prospectus lists a maximum price of $120 a share, while the expected U.S. range is $70 to $78. Both figures are real, and neither means what it first appears to. Here's how to read the timeline, the price, and the financials before you submit an order.
The Timeline Is Real, but the Price Isn't Locked
According to the Anthropic IPO site, the roadshow started November 10 (EST). The final price is expected to be set November 18, subject to regulatory clearance, and shares are expected to begin trading on Nasdaq on November 19. Today is November 12, so you're in the middle of the process.
The roadshow is when underwriters gather demand from institutional investors. The final price reflects that feedback, which is why it can land above or below the estimated range. Most guides describe the price as "set by the company." That's incomplete. The company and its underwriters set it based on what buyers will pay during the roadshow.
Here's the practical difference between the two ways to buy. Shares bought in the IPO are purchased at the offering price, set on November 18. Shares bought after trading begins are purchased at whatever the market price is at that moment. Those are two different prices, and the second one can be well above or below the first.
The $120 Number Is a Ceiling, Not a Target
This is where most readers get tripped up. The European prospectus states a maximum public offering price of $120 per share of Class A common stock. That does not mean you should expect to pay $120.
The company explains that the ceiling was set above the currently estimated U.S. price range of $70 to $78 to let European and Swiss retail investors participate, even if the U.S. final price comes in higher than the estimate. The final price in the European and Swiss retail offerings will equal the final U.S. price. Everyone in the global offering pays the same per-share price.
| Offering figure | Amount | What it actually means |
|---|---|---|
| Estimated U.S. IPO price range | $70 to $78 per share | Current working estimate, not the final price |
| European maximum public offering price | $120 per share | Buffer set above the estimate, not an expected price |
| Final price (U.S. and European retail) | Set November 18 | Same price for all investors in the global offering |
The common advice is "check the prospectus price and plan for that." That's the wrong read. A higher ceiling protects participation. It doesn't predict the outcome. Brokerage fees, commissions, and currency conversion costs are not included in the final price, so your real cost in a non-USD account will be higher than the offer price.
Why the $23.3 Billion Loss Is Mostly an Accounting Event
Here's what the Q3 2026 numbers show, as of September 30, 2026. Revenue was $17.0 billion, more than 12 times the prior year's revenue. Net loss was $23.3 billion. Operating margin was (3)%, and adjusted operating margin was 15%.
The net loss needs context. The company states that the loss includes a $21.9 billion non-cash charge tied to the change in fair value of convertible notes, derivative liabilities, and SAFEs. Those instruments are remeasured when valuation rises, and the change runs through the income statement. So when the company's valuation climbs, the loss balloons even if the core business is performing.
Arithmetically, removing that $21.9 billion leaves about $1.4 billion. Treat that as a rough subtraction, not a reconciliation. Other items sit in the net loss too.
Two cautions matter here:
- Non-cash doesn't mean irrelevant. Convertible notes and SAFEs eventually convert into equity. That's a dilution question, and you should check the prospectus for how those instruments convert.
- Adjusted margin is not GAAP margin. The 15% adjusted operating margin is a non-GAAP measure. The prospectus reconciles it to the (3)% operating margin in the Management's Discussion and Analysis section. Read that reconciliation before you lean on the 15% figure.
The company also reports a compute efficiency gain of more than 4 times since Q1 2025. It defines this as revenue divided by compute and infrastructure expenses, compared with the same ratio in Q1 2025. That's a useful signal of unit economics, but it's a company-defined ratio, and it can move with pricing and product mix.
What the Revenue and Customer Numbers Tell You
The company reports more than 11,900 customers spending $100,000 or more on a trailing twelve-month basis, up more than 12 times year over year. Growth that steep usually comes from a small base, so the absolute scale matters as much as the multiple.
The IPO site also publishes customer case studies. Treat them as vendor-selected evidence, not independent audits. Still, the metrics are specific enough to evaluate:
- Legora (legal AI) reports 4.3 non-billable hours recaptured per lawyer weekly, from an independent study of 31 firms.
- Eli Lilly reports more than 50,000 employees with access to Claude Enterprise, and more than 85% of employees in key functions actively engaging with it.
- Rakuten reports 99.9% code accuracy on complex code modifications and autonomous coding sessions of 7 or more hours.
- Salesforce reports an 18x faster API migration, from 231 days of work to 13.
- Walmart reports more than 110% quarter-over-quarter growth in weekly active users for its Sparky shopping assistant.
Here's the honest read. These numbers show that enterprise adoption is real and deep in some accounts. They don't show how revenue is distributed across the 11,900 customers. A small number of large accounts can carry much of the revenue, and the prospectus's risk factors are where you'll find the concentration detail.
How to Buy Anthropic IPO Shares Without Getting Burned
If you want to participate, the process runs through a brokerage. Here's the sequence the company's FAQ describes:
- Confirm your broker participates. You need an active account with a platform offering the Anthropic IPO.
- Submit an indication of interest. Your broker or app will confirm whether you're eligible when you submit.
- Plan for partial or no allocation. There's no guarantee you'll receive all or any of the shares you request. You should be ready to buy every share you apply for.
- Wait for the final price on November 18. The offering price is set that day, subject to regulatory clearance.
- Check your allocation on November 19. Your broker confirms it on the first trading day.
- Decide whether to buy after trading starts. If you don't get an allocation, or the price looks wrong, you can buy at the prevailing market price instead.
Here's the trap. Getting an allocation at the offer price is not automatically a bargain. Shares can open above or below that price, and you're exposed to whatever happens in the first days of trading. Set a maximum price before you place the order, not after you see the first trade.
The Risks the Headline Numbers Hide
Most people stop at the price range. Don't. The risks that matter most sit in the prospectus, and the summary above only scratches them. Keep these in mind:
- Allocation risk. Demand can exceed supply, and you may get less than you requested or nothing at all.
- Valuation volatility. Because the net loss swings with fair-value remeasurements, reported GAAP results can move sharply even when operations don't.
- Non-GAAP reliance. The 15% adjusted operating margin excludes items the company considers non-core. Check what's excluded.
- Concentration and selection. Customer case studies are chosen by the company. Revenue concentration is in the risk factors.
- Timing dependence. The schedule depends on regulatory clearance. A delay would change when you can trade, not necessarily the company's fundamentals.
Here's the question that matters most: can you afford to lose the money you commit, even if the first-day price disappoints? If the answer is no, the IPO allocation is the wrong place for that money.
Frequently Asked Questions
What is the Anthropic IPO?
The Anthropic IPO is the company's initial public offering of Class A common stock, which will trade on Nasdaq under the ticker ANT. The roadshow started November 10, pricing is expected November 18, and trading is expected November 19, all subject to regulatory clearance. The estimated U.S. price range is $70 to $78 per share.
How do I buy Anthropic IPO shares?
Open an active brokerage account on a platform that participates in the offering, then submit an indication of interest. Your broker will confirm eligibility and your allocation, which you'll see on the first trading day. Allocation isn't guaranteed, so be ready to buy every share you request.
Why does the European prospectus show a $120 price?
The $120 maximum is a ceiling set above the estimated $70 to $78 U.S. range. It lets European and Swiss retail investors participate even if the final U.S. price comes in higher. You'll pay the same final price as everyone else in the global offering, and fees and currency conversion are extra.
When will the Anthropic IPO start trading?
Shares are expected to begin trading on Nasdaq on November 19, following pricing on November 18. Both dates are subject to regulatory clearance, so confirm them with your broker before you plan around them.
Pass this to someone wrestling with the $120 headline and the $23.3 billion loss at the same time. The one thing to do this week: before November 18, read the GAAP-to-adjusted reconciliation in the prospectus and write down the maximum price you'd pay on the first trading day. Then check your broker's fee and currency terms against that number so the Anthropic IPO decision rests on your full cost, not the headline price.